WaveMan
WaveMan · Company
PALI · Palisade Bio, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

PALI Palisade BIO (PALI) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001357459
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
83
13F, latest reported quarter
Conversions, 180 days
8
Codes C/M, not in net · $93 priced

What the filings say about PALI

Insiders, 180 days
-$130.9K net sold
2 buyers · 2 sellers · 0% of sales under a 10b5-1 plan

Palisade BIO insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, PALISADE BIO, INC. insiders sold a net $130.9K of stock across 39 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Williams Donald Allen
Director
BUY
2026-10-05 SECtraded 2026-10-02
10,000
$14.6K
-10.7%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Oct 1, 2026.
  • -0.5% median (-1.5% mean) 90-day return after 5 previous buys.
  • The trade is 0.6% of the 1,590,294 shares held after it.
  • No other insider bought within 30 days.
  • 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Williams Donald Allen bought about $14.6K of PALI on Oct 2, 2026; 83 funds added in the latest 13F quarter.
Williams Donald Allen
Director
BUY
2026-10-05 SECtraded 2026-10-01
10,000
$14.2K
-10.7%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Jan 16, 2026.
  • -0.5% median (-1.5% mean) 90-day return after 5 previous buys.
  • The trade is 0.6% of the 1,580,294 shares held after it.
  • No other insider bought within 30 days.
  • 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Williams Donald Allen bought about $14.2K of PALI on Oct 1, 2026; 83 funds added in the latest 13F quarter.
Baltera Robert Jr.
Director
BUY
2026-07-10 SECtraded 2026-07-09
25,000
$48.9K
-29.6%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Jul 8, 2026.
  • -28.4% median (-29.5% mean) 90-day return after 5 previous buys.
  • The trade is 5.4% of the 461,904 shares held after it.
  • No other insider bought within 30 days.
  • 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Baltera Robert Jr. bought about $48.9K of PALI on Jul 9, 2026; 83 funds added in the latest 13F quarter.
Baltera Robert Jr.
Director
BUY
2026-07-10 SECtraded 2026-07-08
20,000
$39.8K
-29.6%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Jul 7, 2026.
  • -29.1% median (-30.1% mean) 90-day return after 4 previous buys.
  • The trade is 4.6% of the 436,904 shares held after it.
  • No other insider bought within 30 days.
  • 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Baltera Robert Jr. bought about $39.8K of PALI on Jul 8, 2026; 83 funds added in the latest 13F quarter.
Baltera Robert Jr.
Director
BUY
2026-07-08 SECtraded 2026-07-07
30,000
$61.0K
-32.5%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jul 6, 2026.
  • -28.4% median (-30.2% mean) 90-day return after 3 previous buys.
  • The trade is 7.2% of the 416,904 shares held after it.
  • No other insider bought within 30 days.
  • 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Baltera Robert Jr. bought about $61.0K of PALI on Jul 7, 2026, the largest insider purchase at the company on our record; 83 funds added in the latest 13F quarter.
39 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 34 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$130.9K over 180 days
+$28.8K over 90 days
more than 53% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
83 funds bought in last quarter
more than 61% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
22.9% of the float short (float per yahoo 2026-10-26) · 6.1 days to cover · settled 2026-09-30
more than 91% of Pharma & Biotech
What changed in the last 30 days
Oct 5Director Williams Donald Allen bought $28.8K (2 trades, Oct 1 to Oct 2)

Watch PALI

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-18.4%12M
-18%+12%+42%+72%2025-102025-122026-022026-042026-062026-082026-10 2026-07-07 · Finley John David sold $303.3K2026-07-07 · Jones Mitchell Lawrence sold $106.5K2026-07-07 · Baltera Robert Jr. bought $61.0K2026-07-09 · Baltera Robert Jr. bought $48.9K2026-07-06 · Baltera Robert Jr. bought $41.0K2026-07-08 · Baltera Robert Jr. bought $39.8K2026-07-01 · Baltera Robert Jr. bought $39.6K2026-07-02 · Baltera Robert Jr. bought $19.8K2026-10-02 · Williams Donald Allen bought $14.6K2026-10-01 · Williams Donald Allen bought $14.2K2026-01-09 · Williams Donald Allen bought $9.4K2026-01-16 · Williams Donald Allen bought $8.3K2026-02-12 · Finley John David sold $6.8K2026-02-12 · Jones Mitchell Lawrence sold $3.5K2026-07-07 · Finley John David filed to sell $303.3K2026-07-07 · Jones Mitchell Lawrence filed to sell $108.1K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PALI: institutional holders (13F)

13F holdings, latest reported quarter
Soleus Capital Management, L.P.
13,063,687 sh
$27.3M
B Group, Inc.
11,414,285 sh
$23.9M
AMERIPRISE FINANCIAL INC
11,081,434 sh
$23.2M
Jupiter Topco LLC
10,689,452 sh
$22.4M
BlackRock, Inc.
10,436,760 sh
$21.8M

Congress trades in PALI

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PALI planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Finley John David
Filed 2026-07-07
$303.3K
Jones Mitchell Lawrence
Filed 2026-07-07
$108.1K

PALI mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Simplify Propel Opportunities ETF
$941.6K position · as of 2026-06-30
1.2%
Franklin Biotechnology Discovery Fund
$4.0M position · as of 2026-07-31
0.3%
Federated Hermes Kaufmann Small Cap Fund
$5.9M position · as of 2026-07-31
0.2%
iShares Micro-Cap ETF
$1.0M position · as of 2026-06-30
0.1%
NVIT GS Small Cap Equity Insights Fund
$94.6K position · as of 2026-06-30
0.0%
Goldman Sachs Variable Insurance Trust Small Cap Equity Insights Fund
$90.0K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
1 active
2
Phase 2
1 active
1
Phase 3
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · J.D. Finley
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$813.0K
$691.6K
$581.0K
-98%
n/a
2023
$1.3M
$1.0M
$328.7K
-89%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $130.9K sold by insiders over 180 days, 83 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PALI financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$500.0K
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.00x
long-term 2021-12-31 (54 months older than the period end) plus current 2021-12-31 (54 months older than the period end); equity 2026-06-30
Cash flow to debt
-209.08x
TTM operating cash flow over long-term 2021-12-31 (54 months older than the period end) plus current 2021-12-31 (54 months older than the period end)
Return on equity
-51.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-47.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-56.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
2.22x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$106.7M
market value at close 2026-10-23 on 2026-08-06 shares, plus long-term 2021-12-31 (54 months older than the period end) plus current 2021-12-31 (54 months older than the period end), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$0$300.0K$0
Operating income-$18.1M-$14.9M-$13.1M-$15.7M
Net income-$16.8M-$14.4M-$12.3M-$14.3M
EPS (diluted)-0.30-10.19-27.01-16.53
Operating cash flow-$10.8M-$12.2M-$11.1M-$13.4M
Cash$133.4M$9.8M$12.4M$12.4M
SEC XBRL, fiscal years, as known on 2026-10-27

PALI Stock Sonar score 5/7 axes

Find similar shapesCompare

PALI ranks highest on insider conviction (66th percentile) and institutional and government (61st), and lowest on risk and compliance (9th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
47
Inputs
  • Return on equity-51.4% · 53 pct, sector of 545
  • Return on assets-47.7% · 45 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-56.7% · 44 pct, sector of 576
Financial health
45
Inputs
  • Debt to equity0.00x · 85 pct, sector of 352
  • Cash flow to debt-209.08x · 5 pct, sector of 371
Insider conviction
66
Inputs
  • Net Form 4 buying (codes P and S), 180d-$131K · 52 pct, sector of 428
  • Insider buyers, 180d2 · 81 pct, sector of 437
Institutional and government
61
Inputs
  • Funds adding, latest quarter83 · 61 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
9
Inputs
  • Short interest, % of float+22.9% · 11 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+29.7% · 7 pct, sector of 511
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

PALI filings, in plain words

Are Palisade BIO insiders buying or selling PALI?

In the 180 days to 2026-10-27, Palisade BIO insiders were net sellers, a net $130.9K: $279.0K of purchases and $409.9K of sales reported on Form 4, by 2 buyers and 2 sellers.

Read the full summary

In the 180 days to 2026-10-27, Palisade BIO insiders were net sellers of PALI, a net $130.9K across purchases and sales reported on Form 4 by 2 buyers and 2 sellers. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies